5-(3-trifluoromethylbenzyl)-[1,3,4]thiadiazol-2-ylamine | 57552-39-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(3-trifluoromethylbenzyl)-[1,3,4]thiadiazol-2-ylamine
• 英文别名: 5-{[3-(trifluoromethyl)phenyl]methyl}-1,3,4-thiadiazol-2-amine；2-amino-5-(3-trifluoromethylbenzyl)-1,3,4-thiadiazole；2-Amino-5-(3-trifluormethylbenzyl)-1,3,4-thiadiazol；5-[[3-(trifluoromethyl)phenyl]methyl]-1,3,4-thiadiazol-2-amine
• CAS: 57552-39-3
• 化学式: C₁₀H₈F₃N₃S
• 分子量: 259.255
• InChiKey: RRXDVGPGAOJOFL-UHFFFAOYSA-N

物化性质

• 沸点：
  369.5±52.0 °C(Predicted)
• 密度：
  1.435±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-(3-trifluoromethylbenzyl)-[1,3,4]thiadiazol-2-ylamine 、 3,4-二氯苯甲基磺酰氯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以30%的产率得到3,4-dichloro-N-[5-(3-trrfluoromethylbenzyl)-[1,3,4]thiadiazol-2-yl]-benzenesulfonamide
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPK ACTIVATORS
  [FR] COMPOSÉS UTILES COMME MÉDICAMENTS

  摘要：

  公开号：

  WO2010073011A3
• 作为产物：
  描述：

  5-(3-trifluoromethylbenzyl)-[1,3,4]thiadiazol-2-ylamine methansulfonate 在 sodium hydroxide 作用下， 以 乙酸乙酯 为溶剂， 以64%的产率得到5-(3-trifluoromethylbenzyl)-[1,3,4]thiadiazol-2-ylamine
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPK ACTIVATORS
  [FR] COMPOSÉS UTILES COMME MÉDICAMENTS

  摘要：

  公开号：

  WO2010073011A3

文献信息

• ESTER COMPOUND AND MEDICINAL USE THEREOF
  申请人：Japan Tobacco Inc.

  公开号：EP1479666A1

  公开（公告）日：2004-11-24

  A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1") (wherein    R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.;    X is -COO- or -CON(R10)-;    R3 and R4 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.;    R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.;    R8 and R9 are each independently hydrogen atom, C1-C6 alkyl, -CON(R18)(R19) or -COO(R20), etc.;    ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.;    Alk1 and Alk2 are each independently alkanediyl, etc.;    l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.

  一种治疗高脂血症的新型药物，其为酯化合物，由式(1")表示（其中：R1和R2均为氢原子或可选择取代的芳基等；X为-COO-或-CON(R10)-；R3和R4均为氢原子、C1-C6烷基或C1-C6烷氧基等；R5、R6和R7均为氢原子、C1-C6烷基或C1-C6烷氧基等；R8和R9各自独立地为氢原子、C1-C6烷基、-CON(R18)(R19)或-COO(R20)等；环A、环B和环C各自独立地为芳基或杂环残基等；Alk1和Alk2各自独立地为脂肪二亚基等；l和m均为0或1至3的整数），或其前药，或其药学上可接受的盐。该治疗剂能够选择性地抑制小肠中的MTP，因此不会引起脂肪肝等副作用。
• Ester compound and medicinal use thereof
  申请人：Hagiwara Atsushi

  公开号：US20050075367A1

  公开（公告）日：2005-04-07

  A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1″) (wherein R 1 and R 2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R 10 )—; R 3 and R 4 are each hydrogen atom, C 1 -C 6 alkyl or C 1 -C 6 alkoxy, etc.; R 5 , R 6 and R 7 are each hydrogen atom, C 1 -C 6 alkyl or C 1 -C 6 alkoxy, etc.; R 8 and R 9 are each independently hydrogen atom, C 1 -C 6 alkyl, —CON(R 18 )(R 19 ) or —COO(R 20 ), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk 1 and Alk 2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.

  一种治疗高脂血症的新型药物，其为酯化合物，由式（1”）所表示（其中，R1和R2分别为氢原子或可选取代的芳基等；X为—COO—或—CON(R10)—；R3和R4分别为氢原子、C1-C6烷基或C1-C6烷氧基等；R5、R6和R7分别为氢原子、C1-C6烷基或C1-C6烷氧基等；R8和R9分别独立地为氢原子、C1-C6烷基、—CON(R18)(R19)或—COO(R20)等；环A、环B和环C分别独立地为芳基或杂环残基等；Alk1和Alk2分别独立地为脂肪二亚基等；l和m分别为0或1至3的整数），或其前药，或其药学上可接受的盐。该治疗剂能够选择性地抑制小肠中的MTP，从而不会引起脂肪肝等副作用。
• THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE
  申请人：Bouillot Anne Marie Jeanne

  公开号：US20100120669A1

  公开（公告）日：2010-05-13

  The present invention relates to substituted thiadiazole compounds of the formula (I): and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

  本发明涉及公式（I）的取代噻二唑化合物及其药学上可接受的盐，含有它们的制药组合物以及它们在医学上的应用。特别地，本发明涉及用于调节SCD活性的化合物。
• ESTER COMPOUND AND MEDICAL USE THEREOF
  申请人：Hagiwara Atsushi

  公开号：US20100158996A1

  公开（公告）日：2010-06-24

  A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1″) (wherein R 1 and R 2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R 10 )—; R 3 and R 4 are each hydrogen atom, C 1 -C 6 alkyl or C 1 -C 6 alkoxy, etc.; R 5 , R 6 and R 7 are each hydrogen atom, C 1 -C 6 alkyl or C 1 -C 6 alkoxy, etc.; R 9 and R 9 are each independently hydrogen atom, C 1 -C 6 alkyl, —CON(R 18 ) (R 19 ) or —COO(R 20 ), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk 1 and Alk 2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.

  一种治疗高脂血症的新型药物，其为酯化合物，由式（1″）所表示（其中R1和R2分别为氢原子或可选择取代的芳基等；X为—COO—或—CON(R10)—；R3和R4分别为氢原子、C1-C6烷基或C1-C6烷氧基等；R5、R6和R7分别为氢原子、C1-C6烷基或C1-C6烷氧基等；R8和R9分别独立地为氢原子、C1-C6烷基、—CON(R18)(R19)或—COO(R20)等；环A、环B和环C分别独立地为芳基或杂环残基等；Alk1和Alk2分别独立地为脂肪二亚基等；l和m分别为0或1至3的整数），或其前药，或其药学上可接受的盐。该治疗剂选择性地抑制小肠中的MTP，从而不会引起脂肪肝等副作用。
• Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation
  作者：Yoshikazu Uto、Tsuneaki Ogata、Yohei Kiyotsuka、Yuriko Miyazawa、Yuko Ueno、Hitoshi Kurata、Tsuneo Deguchi、Makiko Yamada、Nobuaki Watanabe、Toshiyuki Takagi、Satoko Wakimoto、Ryo Okuyama、Masahiro Konishi、Nobuya Kurikawa、Keita Kono、Jun Osumi

  DOI：10.1016/j.bmcl.2009.05.123

  日期：2009.8

  The continuing investigation of SAR studies of 3-(2-hydroxyethoxy)-N-(5-benzylthiazol-2-yl)-benzamides as stearoyl-CoA desaturase-1 (SCD-1) inhibitors is reported. Our prior hit-to-lead effort resulted in the identification of 1a as a potent and orally efficacious SCD-1 inhibitor. Further optimization of the structural motif resulted in the identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide (37c) with sub nano molar IC(50) in both murine and human SCD-1 inhibitory assays. This compound demonstrated a dose-dependent decrease in the plasma desaturation index in C57BL/6J mice on a non-fat diet after 7 days of oral administration. (C) 2009 Elsevier Ltd. All rights reserved.